1 / 72

Inpatient Skin and Soft Tissue Infections

Inpatient Skin and Soft Tissue Infections . Keri Holmes- Maybank , MD Medical University of South Carolina. Skin and Soft Tissue Infections. Cellulitis Impetigo Erysipelas Abscess Animal bite Human bite Surgical site infection Necrotizing fasciitis. Skin and Soft Tissue Infections.

ivory
Télécharger la présentation

Inpatient Skin and Soft Tissue Infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Inpatient Skin and Soft Tissue Infections Keri Holmes-Maybank, MD Medical University of South Carolina

  2. Skin and Soft Tissue Infections • Cellulitis • Impetigo • Erysipelas • Abscess • Animal bite • Human bite • Surgical site infection • Necrotizing fasciitis

  3. Skin and Soft Tissue Infections • Increasing ER visits and hospitalizations • 29% increase in admissions, 2000 to 2004 • Primarily in age <65 • Presume secondary to community MRSA • 50% cellulitis and cutaneous abscesses • Estimated $10 billion SSTI 2010

  4. IDSA Guidelines MUSC Antibiotic Stewardship & Anti-Infective Subcommittee • “Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances.”

  5. Guidelines • Reduce emergence of resistant organisms • Reduce hospital days • Reduce costs: • Blood cultures • Consultations • Imaging • Hospital days • 2011-Implementation of treatment guidelines • Decreased use of blood cx • Decreased advanced imaging • Decreased consultations • Shorter durations of therapy • Decreased use of anti-pseudomonal • Decreased use of broader spectrum abx • Decreased costs • No change in adverse outcomes

  6. Inpatient Hospitalization • Systemic illness • HR >100 and • Temp >38oC or <36oC and • Systolic bp <90 or decrease of 20 mmHg < baseline • CRP>13 • Marked left shift • Elevated creatinine • Low serum bicarbonate • CPK 2 x the upper limit of normal

  7. Inpatient Hospitalization • Abnormally rapid progression of cellulitis • Worsening infection despite appropriate antibiotics • Tissue necrosis • Severe pain • Altered mental status • Respiratory, renal or hepatic failure • Co-morbidities:  immune compromise, neutropenia, asplenia, preexisting edema, cirrhosis, cardiac failure, renal insufficiency

  8. Skin and Soft Tissue Infections • Indicators of more severe disease: • Low sodium • Low bicarb • High creatinine • New anemia • Low or high wbc • High CRP (associated with longer hospitalization)

  9. Cultures • Blood cultures positive <5% • Needle aspiration 5-40% • Punch biopsy 20-30%

  10. Blood Cultures • HR >100 , Temp >38oC and <36oC, Sys <90mmHg • Lymphedema • Immune compromise/neutropenia/malignancy • Pain out of proportion to exam • Infected mouth or eyes • Unresponsive to initial antibiotics • Water-associated cellulitis • Diabetes • Recurrent or persistent cellulitis • Concern for a cluster or outbreak

  11. Needle Aspiration or Skin Biopsy • HR >100 , Temp >38oC and <36oC, Sys<90mmHg • CRP>13 Marked left shift • Elevated creatinine Low serum bicarb • CPK 2 x upper limit of normal • Immune compromise/neutropenia/malignancy • Diabetes • Animal or human bite wounds

  12. Obtain Careful History • Immune status • Geographic locale • Travel history • Recent trauma or surgery • Previous antimicrobial therapy • Lifestyle - occupation • Hobbies • Animal exposure • Bite exposure

  13. Broaden Antibiotics • If no improvement in systemic signs in 48 hours • If no improvement in skin in 72 hours • As antibiotics kill organisms, released toxins may cause a worsening of skin findings in first 48 hours

  14. Deescalation • Acute skin findings resolving • Afebrile • No signs of systemic illness • Should see systemic signs improvement by 48 hours • Should see skin improvement 3-5 days by at the latest

  15. Cellulitis • 65% relative increase since 1999 • 600,000 admissions annually

  16. Risk Factors for Cellulitis • Obesity • Edema • Venous insufficiency • Lymphatic obstruction • Fissured toe webs • Maceration • Fungal infection • Inflammatory dermatoses – eczema • Repeated cellulitis • Subcutaneous injection or illegal drugs • Previous cutaneous damage • All lead to breaches in the skin for organism invasion

  17. Post-Surgical Risk Factors • Saphenousvenectomy • Axillary node dissection for breast cancer • Gyn malignancy surgery with lymph node dissection *** in conjuction with XRT • Liposuction

  18. Cellulitis • CBC with diff • BMP • Blood cultures • Culture aspiration of leading edge of cellulitis

  19. Non-Purulent Cellulitis • INTACT SKIN • No purulent drainage, no exudate, no associated abscess • Beta hemolytic streptococci • Antibiotic: • Cefazolin • Documented anaphylactic cephalosporin allergy - Vancomycin

  20. Non-Purulent Cellulitis • Deescalation: • Cephalexin • Beta-lactam anaphylaxis - clindamycin • 5 days of treatment

  21. Purulent/Complicated Cellulitis • BROKEN SKIN • Purulent drainage • Exudate • Absence of a drainable abscess

  22. Purulent/Complicated Cellulitis • MRSA coverage • Antibiotics: • Vancomycin

  23. Purulent/Complicated Cellulitis • Deescalation: • Trimethoprim/sulfamethoxazole + cephalexin • Beta lactam anaphylaxis – clindamycin • Sulfa allergy – tetracycline or doxycycline • If sulfa and beta lactam allergies - linezolid • 5 days of treatment

  24. Empiric SSTI algorithm *This algorithmdoes NOTinclude: surgical site infections, diabetic foot ulcers, decubitus ulcers, insect, animal or human bites, or gangrene **Please see order form for guidance (including renal dosing adjustments) If cephalosporin allergic: Vancomycin can be substituted for cefazolin 1 The preferred method of treatment is I&D Clinical Pearl: Treatment should continue for 48 hours prior to determination of clinical failure; SSTIs often appear worse during initial treatment period

  25. Antibiotic De-escalation Criteria • Culture susceptibilities • Clinical response • Clinically stable • Decreased erythema • Decreased edema • Decreased warmth • Resolving leukocytosis • Afebrile Total course of antibiotics is 5 days (i.e. 2 days of IV cefazolin + 3 days of PO cephalexin) Note: Renal dose adjustments are required for patients with CrCL less than 30 mL/min If sulfa allergic: Either tetracyclineor doxycycline can be substituted to replace TMP/SMX If beta-lactam anaphylaxis: Clindamycin (non-severe infection) can be substituted to replace cephalexin, or linezolid can be substituted to replace both TMP/SMX and cephalexin

  26. Secondary Treatment of Cellulitis • Elevation of affected leg • Compression stockings • Treat underlying tineapedis, eczema, trauma • Keep skin well hydrated

  27. Confused with Cellulitis • Acute dermatitis • Lipodermatosclerosis • Deep vein thrombosis • Contact dermatitis • Drug reaction • Foreign body reaction • Gout • Herpes zoster

  28. Abscess

  29. Abscess • ALWAYS, ALWAYS • Incision and drainage

  30. Drainable Abscess <3cm • Incision and drainage • No blood cultures • No aspirate culture • NO ANTIBIOTICS

  31. Abscess • CBC with diff • BMP • Blood cultures • Culture exudate

  32. Abscess –When to Add Antibiotics • Drainable abscess >3cm • Undrainable • Multiple sites of infection • Rapid progression in presence of cellulitis • Systemic illness (fever, hypotension, tachycardia) • Immune compromise • Elderly • Difficult to drain area (hand, face, genitalia) • Lack of response to incision and drainage • Septic phlebitis - multiple lesions • Gangrene

  33. Abscess Antibiotic Coverage • MRSA coverage • Antibiotic: • Vancomycin

  34. Abscess • Deescalation: • Trimethoprim/sulfamethoxazole + cephalexin • Beta lactam anaphylaxis – clindamycin • Sulfa allergy – tetracycline or doxycycline • If sulfa and beta lactam allergies - linezolid • Treatment duration: • Usually 5 days of treatment – 10 maximum

  35. Animal Bites

  36. Animal Bites • Pasteurella – mc organism • Antibiotics: • Ampicillin/sulbactam • Piperacillin/tazobactan • Cefoxitin • Meropenem • Ertapenem (restricted to ID and Surgery) • Tetanus toxoid (if not up to date)

  37. Animal Bites • Deescalation • Amoxicillin/clavulanate • Doxycycline • Treatment duration: • Discontinue abx 3 days after acute inflammation disappears • Usually 5-10 days of treatment

  38. Human Bites

  39. Human Bite • Antibiotics: • Ampicillin/sulbactam • Meropenem • Ertapenem (restricted to ID and Surgery) • Tetanus toxoid (if not up to date) • Closed fist*** • Antibiotics: • Cefoxitin • Ampicillin/sulbactam • Ertapenem(restricted to ID and Surgery) • Tetanus toxoid (if not up to date) • Hand surgery consult***

  40. Human Bites • Deescalation: • Amoxicillin/clavulanate • Moxifloxacin + clindamycin • Trimethoprim/sulfamethoxazole + metronidazole • Treatment duration: • Discontinue abx 3 days after acute inflammation disappears • Usually 5-10 days of treatment if no joint or tendon involvement

  41. Surgical Site Infection

  42. Surgical Site Infection • Pain, swelling, erythema, purulent drainage • Usually have no clinical manifestations for at least 5 days after operation • Most resolve without antibiotics • Open all incisions that appear infected >48 hours after surgery • No antibiotics if temperature <38.5oC and HR <100 bpm

  43. Surgical Site Infection • If temperature >38.5oC or HR >100 bpm: • Trunk, head, neck, extremity • Cefazolin • Clindamycin • Vancomycin if MRSA is suspected • Perineum, gi tract, female gu tract • Cefotetan • Ampicillin/sulbactam • Ceftriaxone + metronidazole or clindamycin • Fluoroquinolone + clindamycin • Treatment duration: • Usually 24-48 hours or for 3 days after acute inflammation resolves

  44. Neutropenia and SSTI’s

  45. Neutropenic Patients with SSTI • ALWAYS blood CULTURES • Initial infection - <7 days neutropenia • Antibiotics • Carbapenems • Cefepime • Ceftazidine • Piperacillin/tazobactam PLUS • Vancomycin • Linezolid (restricted to ID) • Daptomycin (restricted to ID) • (discontinue if culture negative after 72-96 hours)  

  46. Neutropenic Patients with SSTI • Subsequent infection- >7days neutropenia (fungi, viruses, atypical bacteria) • Treatment: • Amphotericin B • Micafungin (may require higher dose and ID consult) • Voriconazole (restricted to ID, Heme/Onc, Critical Care, Pulmonary, and Transplant) PLUS • Carbapenems • Cefepime • Ceftazidine • Piperacillin/tazobactam PLUS • Vancomycin • Linezolid (restricted to ID) • Daptomycin (restricted to ID) • (discontinue if culture negative after 72-96 hours)

  47. Neutropenic Patients with SSTI • Deescalation: • Ciprofloxacin and amoxicillin/clavulanate • Treatment duration: • At least 7 days

  48. Vascular-Access Devices in Neutropenia • Device predisposes to SSTI • 66% Gram positive • Entry site infection • Antibiotics • Tunnel infection and vascular port-pocket infection • Device removal and antibiotics

More Related